演題詳細

ポスター / Poster

ポスター 20 (Poster 20) :Mantle Cell Lymphoma

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F ロイトンホールABCD)
座長・司会
三浦 勝浩 (Katsuhiro Miura):1
1:日本大学 血液膠原病内科
 
前へ戻る

Durable effect of bendamustine for relapsed/refractory indolent lymphoma and mantle cell lymphoma

演題番号 : PS-1-142

安田 峻一郎 (Shunichiro Yasuda):1、渡邊 大介 (Daisuke Watanabe):1、山口 雄 (Takashi Yamaguchi):2、大木 学 (Manabu Ohki):1、御子柴 路朗 (Michiaki Mikoshiba):2、高野 弥奈 (Hina Takano):3、加藤 淳 (Atsushi Kato):1、中根 実 (Minoru Nakane):2

1:Division of Hematology,Japanese Red Cross Society Hospital Musashino、2:Division of Oncology,Japanese Red Cross Society Hospital Musashino、3:Department of Blood Transfusion,Japanese Red Cross Society Hospital Musashino

 

Background and methods: More than two years have passed since bendamustine(BEN) was approved for relapsed/refractory indolent lymphoma and mantle cell lymphoma (MCL) in Japan. In this study we retrospectively analyzed patients treated with BEN-containing regimen in our institute from December 2012 to March 2013, and evaluated the efficacy, including progression free survival (PFS) and OS. Results: 17 patients (10 male, 7 female) were treated. The median age was 68 (range 38-84). Eleven patients had follicular lymphoma, 4 mantle cell lymphoma, 1 marginal zone lymphoma, and 1 SLL/CLL. The mean prior treatment number was 2.2 (range 1-5). BEN monotherapy was applied to 5 patients, and others were treated with rituximab. The median cycle of treatment was 4 (range 1-6). Adverse effect and progressive disease were the main reasons for discontinuation. Eight patients achieved CR, including 7 confirmed by PET-CT, and 75% overall response was observed. PFS was 370 days, and especially patients who were treated with more than 4 cycles of BEN showed prolonged PFS compared with 3 or less cycles (median not reached, and 230 days, respectively). 15 patients are still alive , and median OS was not reached. Grade 3/4 hematological and non-hematological AE developed in 15 and 4 patients, leading to neutropenia, rash and others, ceasing the therapy. Conclusion: BEN alone or in combination with rituximab is effective and tolerable treatment for relapsed/refractory indolent lymphoma and MCL. Durable response was observed in patients treated more than 4 cycles.

前へ戻る